Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 for tolerance in liver transplantation
2017-000177-37Phase 4Terminated
- Sponsor
- King's College London
- Start
- Aug 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aldesleukin in liver transplant, sponsored by King's College London. Primary endpoint: Successful immunosuppression withdrawal at 1 year. Started Aug 2017; status: terminated.
02
Drugs
aldesleukin
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2017-000177-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000177-37.